Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum

Journal of Immunological Methods

Volumn 233, Issue 1-2, 2000, Pages 57-65

  Conway Jr , Thomas F ^a   Sabel, Michael S ^b   Sugano, Masahiko ^a   Frelinger, John G ^c   Egilmez, Nejat K ^a   Chen, Fang An ^a   Bankert, Richard B ^a  

^a Roswell Cancer Institute   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

PSA; SCID mice; Serum marker; Transfection; Xenograft

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; INOCULATION; LUNG NON SMALL CELL CANCER; MALE; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT; SERUM; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROSTATE-SPECIFIC ANTIGEN; RABBITS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0343340034     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00190-8     Document Type: Article

References (19)

1. Alosco T.R., Croy B.A., Gansbacher B., Wang H.Q., Rao U., Bankert R.B. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells. Cancer Immunol. Immunother. 36:1993;364.
2. Arguello F., Sterry J.A., Zhao Y.Z., Alexander M.R.A., Shoemaker R.H., Cohen H.J. Two serologic markers to monitor the engraftment, growth and treatment response of human leukemias in severe combined immunodeficient mice. Blood. 87:1996;4325.
3. Egilmez N.K., Cuenca R., Yokota S., Sorgi F., Bankert R.B. In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery. Gene Therapy. 3:1996;607.
4. Egilmez N.K., Jong Y.S., Iwanuma Y., Jacob J.S., Santos C.A., Chen F.A., Mathiowitz E., Bankert R.B. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunol. Immunother. 46:1998;21.
5. Gleave M.E., Hsieh J.T., Wu H.C., von Eschenbach A.C., Chung L.W.K. Serum PSA levels in mice bearing human prostate metastatic LNCaP cells tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 52:1992;1598.
6. Hiramoto R., Ghanta V., Durant J.R. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model. Cancer Res. 35:1975;1309.
7. Iwanuma Y., Chen F.A., Egilmez N.K., Takita H., Bankert R.B. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res. 57:1997;2937.
8. Jansen B., Vallera D.A., Jaszcz W.B., Nguyen D., Kersey J.H. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res. 52:1992;1314.
9. Kuriyama M., Wang M.C., Papsidero L.D., Killian C.S., Inaji H., Slack N.H., Nashiura T., Murphy G.P., Chu T.M. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 40:1980;4658.
10. Oesterling J.E. Prostate Specific Antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:1991;907.
11. Reddy S., Piccone D., Takita H., Bankert R.B. Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res. 47:1987;2456.
12. Sakakibara T., Chen F.A., Kida H., Kunieda K., Cuenca R.E., Martin F.J., Bankert R.B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastasis of human lung tumor xenografts. Cancer Res. 56:1996;3743.
13. Tsunenari T., Koishihara Y., Nakamura A., Moriya M., Ohkawa H., Goto H., Shimazaki C., Nakagawa M., Ohsugi Y., Kishimoto T., Akamatsu K. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood. 90:1997;2437.
14. Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. Purification of a human prostate-specific antigen. Invest. Urol. 17:1979;159.
15. Wei C., Storozynsky E., McAdam A.J., Yeh K.Y., Tilton B.R., Willis R.A., Barth R.K., Looney R.J., Lord E.M., Frelinger J.G. Expression of human prostate specific antigen in a mouse tumor line reduces tumorigenicity and elicits PSA-specific cytotoxic T-lymphocytes. Cancer Immunol. Immunother. 42:1996;362.
16. Williams S.S., Umemoto T., Kida H., Repasky E.A., Bankert R.B. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies. J. Immunol. 149:1992;2830.
17. Williams S.S., Alosco T.R., Croy B.A., Bankert R.B. The study of human neoplastic disease in severe combined immunodeficient mice. Laboratory Animal Science. 43:1993;1.
18. Williams S.S., Alosco T.R., Mayhew E., Lasic D.D., Martin F.J., Bankert R.B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 53:1993;3964.
19. Williams S.S., Chen F.A., Kida H., Yokota S., Miya K., Kato M., Barcos M.P., Wang H.Q., Alosco T., Umemoto T., Croy B.A., Repasky E.A., Bankert R.B. Engraftment of human tumor infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J. Immunol. 156:1996;1908.